Why AC Immune Stock Zoomed Almost 15% Higher Today

Eli Lilly amended its 2018 collaboration with AC Immune to provide a CHF10 million (~$12.5M) upfront payment and potential milestone payments totaling more than CHF1.7 billion (roughly ~$2.1B). AC Immune's shares jumped nearly 15% on the news; the companies retain royalties potential and IND-enabling studies are expected to start imminently, advancing the Morphomer program toward clinical dosing.

Analysis

The Lilly collaboration functions as a de-risking stamp rather than a value-creating cash engine in the near term: it materially increases the posterior probability that AC Immune’s program survives IND-enabling work and enters human dosing, which compresses binary tail risk and should structurally lift comparable small-cap neurodegenerative names trading on partnership optionality. A second-order effect is a likely re-pricing of licensing comps in the Alzheimer/misfolded-protein niche — expect earlier-stage deal terms to ratchet up (higher up-fronts, tighter options) as Big Pharma competes for platforms with translational biomarkers and humanized assays. Operationally, IND-enabling ramp will drive demand for specialized CRO/CDMO capacity (toxicology, GLP batches, centralized CSF biomarker labs), creating short-term margin pressure for those vendors but multi-year revenue visibility if the program advances.

Tail risks are classic binary biotech: safety or lack of target engagement in Phase 1 will wipe out the re-rating; regulatory skepticism about surrogate biomarkers or failure to establish a predictive PD signal would similarly reverse sentiment. Timing matters — IND-enabling to first-in-human dosing is likely a 6–18 month process, with meaningful value inflection only on PD/safety readouts 12–36 months out; liquidity and implied volatility will remain elevated during that window. External catalysts that could reverse the trend quickly include a competitor’s positive pivotal that invalidates the target hypothesis or a high-profile safety scare in mechanistically similar molecules.

From a portfolio-construction standpoint, this is a convex bet: small allocated exposure to AC Immune captures multiple binary upside streams (milestones + royalties) while preserving downside via option structures or cross-hedges. The market has probably not fully discounted the CRO/CDMO knock-on winners nor the re-pricing of licensing comps — but it has likely priced in the headline partnership, making pure equity exposure higher risk versus structured entry. For broader hedges or liquidity plays, consider using liquid large-cap names with asymmetric optionality to control portfolio delta.

Key Decisions for Investors

• Long ACIU via defined-risk call spread: buy 18–24 month ACIU LEAP call spread sized 0.5% NAV (long lower strike, short higher strike) to capture milestone re-pricing while capping premium; target 3:1 upside/downside if Phase 1 PD signal observed, cut to 50% at first safety signal.
• Event-driven equity exposure: tactical long ACIU common sized 0.25–0.75% NAV ahead of IND-enabling filings (6–12 months), funded by selling 1–3 month out-of-the-money calls on a liquid biotech ETF (e.g., XBI) to harvest premium and reduce carry — expect volatile 30–60% swings.
• Hedge binary program risk: buy 12–24 month put protection on a biotech index/ETF (XBI or IBB) sized to offset 60–80% of ACIU position’s delta — protects against sector-wide derisking if target hypothesis fails.
• Relative-value idea: overweight boutique CRO/CDMO names with near-term capacity exposure (small-cap suppliers) vs large-cap pharma outsourcing buckets; hold 12–36 months, target 20–40% nominal upside as IND demand materializes, stop-loss if headline trial failure probability rises sharply.
• Contrarian reduce: avoid levering into straight equity positions on ACIU >1% NAV; if implied volatility contracts post-announcement, consider trimming option premium and redeploying into longer-dated, cheaper convexity on the next material catalyst.